Anaïs M'Houmadi

Title: Anaïs M'Houmadi: Innovator in Cancer Immunotherapy

Introduction

Anaïs M'Houmadi is a notable inventor based in Alfortville, France. He has made significant contributions to the field of cancer immunotherapy through his innovative research and development of immunogenic peptides.

Latest Patents

M'Houmadi holds a patent for "Immunogenic peptides of the cyclin B1 tumor antigen." This invention relates to peptides that comprise at least one CD4T epitope, which is immunodominant in vitro. These peptides are capable of stimulating a specific human CD4T lymphocyte response in subjects with varied HLA II molecules. The peptides are intended for use as a cancer vaccine and as a reagent for the diagnosis of cancer or for immunomonitoring the cellular response against cyclin B1 during cancer or anticancer treatment. He has 1 patent to his name.

Career Highlights

Anaïs M'Houmadi is associated with the Commissariat à l'Énergie Atomique et aux Énergies Alternatives, where he continues to advance his research in cancer immunotherapy. His work focuses on developing innovative solutions to combat cancer through immunological approaches.

Collaborations

M'Houmadi collaborates with esteemed colleagues such as Bernard Maillere and Claire Chevaleyre, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Anaïs M'Houmadi is a pioneering inventor whose work in immunogenic peptides holds promise for advancing cancer treatment. His contributions to the field exemplify the importance of innovation in addressing critical health challenges.